2-(4-phenyl-1H-imidazol-2-yl)ethanamine | 88883-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-phenyl-1H-imidazol-2-yl)ethanamine
• 英文别名: 2-(5-phenyl-1H-imidazol-2-yl)ethan-1-amine；2-(5-phenyl-1H-imidazol-2-yl)ethanamine
• CAS: 88883-87-8
• 化学式: C₁₁H₁₃N₃
• 分子量: 187.244
• InChiKey: HSNDOBKMAPOQBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-[2-(4-Phenyl-1H-imidazol-2-yl)-ethyl]-isoindole-1,3-dione 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以56%的产率得到2-(4-phenyl-1H-imidazol-2-yl)ethanamine
  参考文献：
  名称：

  异组胺

  摘要：

  描述了从 3-氯丙酰亚胺酸甲酯或 3-邻苯二甲酰亚胺丙醛开始合成异组胺（2-（2-氨基乙基）-咪唑）和 4-单-和 4,5-二取代衍生物的两种方法及其组胺样活性决心，决意，决定。

  DOI：

  10.1002/ardp.19843170104

文献信息

• [EN] AMIDE COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS AMIDES UTILISÉS EN TANT QU'INHIBITEURS DE LA TRYPTOPHANE HYDROXYLASE
  申请人：KAROS PHARMACEUTICALS INC

  公开号：WO2016109501A1

  公开（公告）日：2016-07-07

  The present invention is directed to amide compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment or prevention of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, fibrotic, and low bone mass diseases, as well as cancer.

  本发明涉及酰胺化合物，这些化合物是色氨酸羟化酶（TPH）的抑制剂，特别是异构体1（TPH1），可用于治疗或预防与外周血清素相关的疾病或紊乱，例如，胃肠道、心血管、肺部、炎症、代谢、纤维化和低骨密度疾病，以及癌症。
• [EN] NEW STABLE SOLVATE CRYSTALLINE FORMS OF ELUXADOLINA<br/>[FR] NOUVELLES FORMES CRISTALLINES DE SOLVATE STABLES D'ELUXADOLINE
  申请人：EUTICALS SPA

  公开号：WO2017153471A1

  公开（公告）日：2017-09-14

  Two new stable non stoichiomeric crystalline solvate forms of Eluxadoline with 4-methylpentan-2-one or methyl terf-butylether are described as well as the process for the production of the same. The solvate form with 4-methylpentan-2-one is defined as "Eluxadoline form gamma" whereas the solvate with methyl terfbutylether is defined as "Eluxadoline form delta". Form gamma may be obtained by slurrying Eluxadoline amorphous form in 4-methylpentan-2-one; form delta may be obtained by slurrying Eluxadoline form gamma in methyl terf-butylether.

  介绍了两种新的稳定的非化学计量结晶溶剂化物形式的Eluxadoline，其中一种是与4-甲基戊酮或甲基叔丁基醚结晶的形式，同时还介绍了它们的生产过程。用4-甲基戊酮溶剂的溶剂化物形式被定义为“Eluxadoline γ形”，而用甲基叔丁基醚的溶剂化物形式被定义为“Eluxadoline δ形”。γ形可以通过在4-甲基戊酮中搅拌Eluxadoline非晶态形式来获得；δ形可以通过在甲基叔丁基醚中搅拌Eluxadoline γ形来获得。
• (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators
  申请人：Pfizer Limited

  公开号：US20140296313A1

  公开（公告）日：2014-10-02

  The present invention is directed to imidazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new imidazole Na V 1.8 modulators of formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Na V 1.8 modulators useful in the treatment of a wide range of disorders, particularly pain.

  本发明涉及咪唑衍生物，其在医学上的应用，包含它们的组合物，制备它们的方法以及用于这些方法的中间体。更具体地，本发明涉及一种新的咪唑NaV1.8调节剂，其化学式为(I)或其药学上可接受的盐，其中R1、R2、R3、R4和R5如描述中所定义。NaV1.8调节剂在治疗各种疾病，特别是疼痛方面具有用途。
• Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US11221329B2

  公开（公告）日：2022-01-11

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

  本发明提供了用于治疗和/或减轻神经或神经发育疾病或紊乱症状的方法，该疾病或紊乱的特征是某些离子通道的异位表达，特别是 Nav1.8 亚型 SCN10a 钠通道或 KCNQ1 钾通道在中枢神经系统（CNS）神经细胞中的异位表达。8亚型SCN10a钠通道或KCNQ1钾通道的方法，该方法通过向有需要的受试者施用一种或两种这些离子通道的拮抗剂，特别是SCN10a的拮抗剂，以阻断、减少或抑制异常的中枢神经系统（CNS）离子通道、或抑制异常的中枢神经系统神经元离子通道表达和/或活性，使与神经系统和神经发育疾病或紊乱相关的行为和认知缺陷正常化，从而治疗和/或减轻神经系统或神经发育疾病或紊乱的症状。可通过所述方法治疗的此类疾病或紊乱的例子包括皮特-霍普金斯综合征（PTHS）、自闭症、自闭症谱系障碍、精神分裂症、18q 综合征等。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2291187A2

  公开（公告）日：2011-03-09